ArticleWorld journal of urology2026
Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment to: "Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type".World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess oncological outcomes and prognostic factors for recurrence and survival after robot-assisted radical cystectomy (RARC) according to the type of urinary diversion.
methodsWe conducted a retrospective single-center study including 109 patients who underwent RARC between 2008 and 2022. Clinical, pathological, and follow-up data were analyzed and compared between patients with ileal conduit (Bricker) and those with orthotopic neobladder. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier curves. Prognostic factors were evaluated using logistic regression and Cox proportional hazards models.
resultsAmong the 109 patients, 74 (67.9%) underwent ileal conduit diversion and 35 (32.1%) received an orthotopic neobladder. Patients in the neobladder group were younger, in better general health (ASA score), and more frequently treated with neoadjuvant chemotherapy (59.6% vs. 21.4%, p = 0.002). Complete pathological response (pT0) was significantly more common after neobladder reconstruction (42.9% vs. 14.9%, p = 0.006). At 5 years, RFS (83.9% vs. 64.7%, p = 0.03) and OS (64.9% vs. 41.8%, p = 0.02) were higher in the neobladder group. On multivariate analysis, impaired health status (ASA 3-4), ileal conduit diversion, lymph node involvement, muscle-invasive disease at cystectomy, and positive surgical margins were identified as independent predictors of worse RFS and OS at both 2 and 5 years.
conclusionPatients undergoing orthotopic neobladder reconstruction demonstrated better oncological outcomes, primarily reflecting their more favorable baseline characteristics. Nonetheless, lymph node involvement, pathological tumor stage, and patient general health remain the strongest determinants of recurrence and mortality following RARC.
Indexed as
Identifiers
41533072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.